Small non-mucinous bronchioloalveolar carcinoma with anaplastic lymphoma kinase immunoreactivity: A novel ALK fusion gene?

Cancer Science

Volumn 103, Issue 2, 2012, Pages 390-392

  Yamamoto, Morio ^a   Takeuchi, Kengo ^b   Shimoji, Masaki ^a   Maniwa, Tomohiro ^a   Isaka, Mitsuhiro ^a   Nakagawa, Kazuo ^a   Ohde, Yasuhisa ^a   Kondo, Haruhiko ^a   Nakajima, Takashi ^a  

^a SHIZUOKA CANCER CENTER   (Japan)

^b CANCER INSTITUTE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; ECHINODERM MICROTUBULE ASSOCIATED PROTEIN LIKE 4; FLUORODEOXYGLUCOSE F 18; PROTEIN TYROSINE KINASE; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; DISEASE FREE SURVIVAL; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; FUSION GENE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; LUNG ALVEOLUS CELL CARCINOMA; LUNG SEGMENTECTOMY; LYMPHOCYTIC INFILTRATION; PRIORITY JOURNAL; SMALL NONMUCINOUS BRONCHIOLOALVEOLAR CARCINOMA; SURGICAL TECHNIQUE;

ADENOCARCINOMA, BRONCHIOLO-ALVEOLAR; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; LUNG NEOPLASMS; MIDDLE AGED; ONCOGENE PROTEINS, FUSION; RECEPTOR PROTEIN-TYROSINE KINASES;

EID: 84856419064     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2011.02136.x     Document Type: Article

References (13)

1. Soda M, Choi YL, Enomoto M et al. Identificaion of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 2007; 448: 561-6.
2. Inamura K, Takeuchi K, Togashi Y et al. EML4-ALK fusion is linked to histological characteristics in a subset of lung cancers. J Thorac Oncol 2008; 3: 13-7.
3. Inamura K, Takeuchi K, Togashi Y et al. EML4-ALK lung cancers are characterized by rare other mutations, a TTF-1 cell lineage, an acinar histology, and young onset. Mod Pathol 2009; 22: 508-15.
4. Shaw AR, Yeap BY, Mino-Kenudson M et al. Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. J Clin Oncol 2009; 27: 4247-53.
5. Takeuchi K, Choi YL, Togashi Y et al. KIF5B-ALK, a novel fusiononcokinase identification by an immunohistochemistry-based diagnostic system for ALK-positive lung cancer. Clin Cancer Res 2009; 15: 3143-9.
6. Rodig SJ, Mino-Kenudson M, Dacic S et al. Unique clinicopathologic features characterize ALK-rearranged lung adenocarcinoma in the western population. Clin Cancer Res 2009; 15: 5216-23.
7. Travis WD, Brambilla E, Noguchi M et al. International association for the study of lung cancer/American Thoracic Society/Europian Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma. J Thorac Oncol 2011; 6: 244-85.
8. Tanaka H, Yanagisawa K, Shinjo K et al. Lineage-specific dependency of lung adenocarcinomas on the lung development regulator TTF-1. Cancer Res 2007; 67: 6007-11.
9. Gamal G, Sano T, Sakurai S, Kawashima O, Sugano M, Nakajima T. Immunohistopathological re-evaluation of adenocarcinoma of the lung with mixed subtypes using a tissue microarray technique and hierarchical clustering analysis. Pathol Int 2007; 57: 765-74.
10. Mino-Kenudson M, Chirieac LR, Law K, Hornick JL et al. A novel, highly sensitive antibody allows for the routine detection of ALK-rearranged lung adenocarcinomas by standard immunohistochemistry. Clin Cancer Res 2010; 16: 1561-71.
11. Rikova K, Guo A, Zeng Q et al. Globalsurvey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer. Cell 2007; 131: 1190-203.
12. Shinmura K, Kageyama S, Tao H et al. EML4-ALK fusion transcripts, but no NPM-, TPM3-, CLTC-, ATIC-, or TFG-ALK fusion transcripts, in non-small cell lung carcinomas. Lung Cancer 2008; 61: 163-9.
13. Kosaka T, Yatabe Y, Endoh H et al. Mutations of the Epidermal Growth Factor Receptor gene in lung cancer: biological and clinical implications. Cancer Res 2004; 64: 8919-23.